UCHealth, Children’s Hospital Colorado, the University of Colorado Anschutz and Bayer announced a new strategic alliance for collaboration in clinical trials on July 7.
The alliance will support innovations in clinical trial design and implementation while expediting clinical research and expanding patient access to clinical trials.
Initial Research Focus Areas
Oncology · Cardiovascular disease · Chronic kidney disease · Neurodegenerative disease · Cell and gene therapy · Women’s health · Ophthalmology
As part of the alliance, UCHealth University of Colorado Hospital was selected as a Phase III clinical trial site for an investigational cellular therapy for advanced Parkinson’s disease. The study brings CU Anschutz neurologists and neurosurgeons experienced in caring for patients with advanced Parkinson’s disease access to a one-time cell-based treatment currently only available in clinical trials. Additional pediatric trial opportunities are also being explored with physician-scientists at Children’s Hospital Colorado.
“UCHealth’s goal is to offer innovations like this through our academic partners in locations across Colorado.”
Dr. Jean Kutner, Chief Academic Officer, UCHealth; Distinguished Professor, CU Anschutz School of Medicine